Literature DB >> 33372785

Identification of Deamidated Peptides in Cytokine-Exposed MIN6 Cells through LC-MS/MS Using a Shortened Digestion Time and Inspection of MS2 Spectra.

Aïsha Callebaut1, Rita Derua2,3, Saurabh Vig1, Thomas Delong4, Chantal Mathieu1, Lut Overbergh1.   

Abstract

Enzymatic deamidation, the conversion of glutamine (Gln) into glutamic acid (Glu) residues, mediated by tissue transglutaminase enzymes, can provoke autoimmunity by generating altered self-epitopes, a process well-known in celiac disease and more recently also described in type 1 diabetes (T1D). To identify deamidated proteins, liquid chromatography-tandem mass spectrometry is the method of choice. However, as nonenzymatic deamidations on asparagine (Asn) and to a minor extent on Gln are frequently induced in vitro during proteomics sample preparation, the accurate detection of in vivo deamidation can be hampered. Here we report on the optimization of a method to reduce in vitro generated deamidation by 70% using improved trypsin digestion conditions (90 min/pH 8). We also point to the critical importance of manual inspection of MS2 spectra, considering that only 55% of the high quality peptides with Gln deamidation were assigned correctly using an automated search algorithm. As proof of principal, using these criteria, we showed a significant increase in levels of both Asn and Gln deamidation in cytokine-exposed murine MIN6 β-cells, paralleled by an increase in tissue transglutaminase activity. These findings add evidence to the hypothesis that deamidation is occurring in stressed β-cell proteins and can be involved in the autoimmune process in T1D.

Entities:  

Keywords:  artifactual deamidation; autoimmunity; enzymatic deamidation; type 1 diabetes

Year:  2020        PMID: 33372785     DOI: 10.1021/acs.jproteome.0c00801

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  6 in total

1.  T-Cell Receptor/HLA Humanized Mice Reveal Reduced Tolerance and Increased Immunogenicity of Posttranslationally Modified GAD65 Epitope.

Authors:  Yi Jing; Yuelin Kong; John McGinty; Gabriele Blahnik-Fagan; Thomas Lee; Stephanie Orozco-Figueroa; Matthew L Bettini; Eddie A James; Maria Bettini
Journal:  Diabetes       Date:  2022-05-01       Impact factor: 9.461

Review 2.  Posttranslational modifications in diabetes: Mechanisms and functions.

Authors:  Bin Chen; Jianing Zhong; Ang Hu; Haohong Zou
Journal:  Rev Endocr Metab Disord       Date:  2022-06-13       Impact factor: 9.306

3.  CD8+ T Cells Variably Recognize Native Versus Citrullinated GRP78 Epitopes in Type 1 Diabetes.

Authors:  Marie Eliane Azoury; Fatoumata Samassa; Mijke Buitinga; Laura Nigi; Noemi Brusco; Aïsha Callebaut; Matthieu Giraud; Magali Irla; Ana Ines Lalanne; Alexia Carré; Georgia Afonso; Zhicheng Zhou; Barbara Brandao; Maikel L Colli; Guido Sebastiani; Francesco Dotta; Maki Nakayama; Decio L Eizirik; Sylvaine You; Sheena Pinto; Mark J Mamula; Yann Verdier; Joelle Vinh; Soren Buus; Chantal Mathieu; Lut Overbergh; Roberto Mallone
Journal:  Diabetes       Date:  2021-09-24       Impact factor: 9.461

4.  Neoepitopes in Type 1 Diabetes: Etiological Insights, Biomarkers and Therapeutic Targets.

Authors:  Teresa Rodriguez-Calvo; James D Johnson; Lut Overbergh; Jessica L Dunne
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 7.561

5.  Aberrant expression of transglutaminase 2 in pancreas and thymus of NOD mice underscores the importance of deamidation in neoantigen generation.

Authors:  Aїsha Callebaut; Ylke Bruggeman; Cloé Zamit; Fernanda Marques Câmara Sodré; Magali Irla; Chantal Mathieu; Mijke Buitinga; Lut Overbergh
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-26       Impact factor: 6.055

Review 6.  Citrullination and PAD Enzyme Biology in Type 1 Diabetes - Regulators of Inflammation, Autoimmunity, and Pathology.

Authors:  Mei-Ling Yang; Fernanda M C Sodré; Mark J Mamula; Lut Overbergh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.